MedPath

Vertex and Bluebird Bio Initiate Infusions of Sickle Cell Gene Therapies

• Vertex Pharmaceuticals and CRISPR Therapeutics have begun infusions of their sickle cell gene therapy, Casgevy, marking a significant advancement in treatment. • Bluebird Bio has also started administering its sickle cell gene therapy, Lyfgenia, to patients after receiving FDA approval. • The initiation of these gene therapies represents a breakthrough, though the treatment process is lengthy and complex, potentially taking up to a year. • Analysts predict substantial revenue generation for both Casgevy and Lyfgenia, with peak sales for Casgevy potentially reaching $3.6 billion.

Following FDA approval, Vertex Pharmaceuticals and CRISPR Therapeutics, along with Bluebird Bio, have initiated infusions of their respective gene therapies for sickle cell disease. This marks a significant step forward in the treatment of this debilitating condition, offering new hope to patients who have long awaited more effective options.

First Patients Receive Gene Therapies

Vertex confirmed that patients have begun receiving Casgevy, their CRISPR-based gene therapy, after initial concerns about delays following its approval. Bluebird Bio also reported that patients are now receiving infusions of Lyfgenia. These developments signal a turning point in the treatment landscape for sickle cell disease.

Complexities of Treatment Uptake

Experts anticipated a slow uptake of gene therapies due to the lengthy and complex treatment process, which can take up to a year. Stuart Arbuckle, Chief Operating Officer at Vertex, acknowledged the complexity, stating, "We have always known that Casgevy offers an enormous advancement for patients... the patient journey... is long and complex."

Market Expectations and Revenue Projections

Despite the slow start, analysts are optimistic about the financial prospects of both therapies. William Blair estimates that peak sales for Casgevy could reach $3.6 billion. Bluebird Bio CFO James Sterling indicated that investors can expect approximately two quarters between initial cell collection and revenue recognition for Lyfgenia.

Patient Demand and Treatment Timelines

Sterling clarified that the pace of treatment initiation is not due to a lack of demand but rather the time-consuming nature of the process. Patients are scheduling treatments months in advance, often aligning with significant life events, given the commitment required for gene therapy.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Liver Cirrhosis Clinical Trial Pipeline Gains Momentum

The liver cirrhosis treatment market is experiencing significant growth, driven by advancements in antiviral therapies and regenerative medicine. Over 30 companies are actively developing new treatments, with several promising therapies currently in clinical trials.

Sickle Cell Gene Therapy Adoption Slow Despite Curative Potential

Initial uptake of sickle cell gene therapies Casgevy and Lyfgenia has been slow, with only a few patients infused despite FDA approval a year ago.
Complex treatment processes, including extensive consultations, preparatory chemotherapy, and bespoke manufacturing, contribute to the slow adoption.

CASGEVY Shows Durable Clinical Benefits in Sickle Cell Disease and Beta Thalassemia

Long-term data from clinical trials demonstrate the sustained benefits of CASGEVY™ in patients with severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
In SCD, 93% of evaluable patients were free from vaso-occlusive crises (VOCs) for at least 12 consecutive months, with a mean VOC-free duration of 30.9 months.

CMS Access Model Offers Hope for Cell and Gene Therapies in Sickle Cell Disease

The Biden Administration has launched the Cell and Gene Therapy Access Model to negotiate outcomes-based agreements for therapies, starting with sickle cell disease.
Lyfgenia and Casgevy manufacturers have agreed to participate, potentially improving patient access through Medicaid.

Sickle Cell Disease Treatment Landscape Faces Challenges Despite Gene Therapy Advances

The sickle cell disease treatment landscape is facing challenges, including access barriers to gene therapies and the withdrawal of Pfizer's Oxbryta due to safety concerns.
Gene therapies like Vertex and CRISPR Therapeutics' Casgevy and bluebird bio's Lyfgenia, while potentially curative, are limited by high costs, complex administration, and toxicity.

Eisai and Biogen Pursue Subcutaneous Leqembi Approval for Alzheimer's

Eisai and Biogen have completed their application for a subcutaneous formulation of Leqembi, aiming for approval in 2025.
The subcutaneous version offers a less burdensome, once-weekly autoinjector, potentially enhancing patient convenience and drug uptake.

Casgevy Faces Hurdles to Profitability Despite Landmark Approval for Sickle Cell Disease

CRISPR Therapeutics and Vertex Pharmaceuticals' Casgevy, the first CRISPR-Cas9 gene editing therapy approved for sickle cell disease, faces a slow rollout due to complex patient preparation processes.
Reimbursement challenges, particularly with Medicaid and Medicare, and the high list price of $2.2 million, complicate access to Casgevy.

FDA Approves Gene Therapies Casgevy and Lyfgenia for Sickle Cell Disease

The FDA has approved Casgevy (Vertex Pharmaceuticals) and Lyfgenia (Bluebird Bio) as novel gene therapies for sickle cell disease, offering potential long-term solutions.
Casgevy utilizes CRISPR/Cas9 technology to reactivate fetal hemoglobin production, while Lyfgenia employs a viral vector to introduce a functional hemoglobin gene.

CRISPR Clinical Trials: A 2024 Update

The article provides an update on CRISPR-based therapies, highlighting the first-ever approval of a CRISPR-based medicine, Casgevy, for sickle cell disease and transfusion-dependent beta thalassemia. It discusses the progress, challenges, and future directions of CRISPR clinical trials across various diseases, including blood disorders, chronic bacterial infections, protein-folding diseases, inflammatory diseases, cancers, cardiovascular disease, HIV/AIDS, diabetes, and autoimmune diseases.

FDA Approves CRISPR-Based Gene Therapy Casgevy for Transfusion-Dependent Beta Thalassemia

The FDA has approved Casgevy, a CRISPR-based gene therapy, for treating transfusion-dependent beta thalassemia, marking the second major U.S. approval for CRISPR technology.
Casgevy modifies patients' blood cells to increase hemoglobin production, reducing or eliminating the need for regular blood transfusions in individuals with the genetic disorder.

Reference News

[1]
Patients At Last Begin Receiving Vertex-CRISPR and Bluebird Sickle Cell Gene Therapies
biospace.com · Sep 17, 2024

Infusions of Vertex's Casgevy and bluebird bio's Lyfgenia for sickle cell treatment have begun, marking a breakthrough. ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy